CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply
- Author(s)
- Fennell, DA; Griffiths, G; Ottensmeier, C; Hanna, GG; Danson, S; Szlosarek, P; Nye, M;
- Details
- Publication Year 2022-01,Volume 23,Issue #1,Page e14-e15
- Journal Title
- Lancet Oncology
- Publication Type
- Correspondence
- Keywords
- Humans; Immunotherapy/adverse effects; *Mesothelioma/drug therapy; *Mesothelioma, Malignant
- Department(s)
- Radiation Oncology
- PubMed ID
- 34973224
- Publisher's Version
- https://doi.org/10.1016/S1470-2045(21)00722-1
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-24 05:32:24
Last Modified: 2024-10-24 05:33:22